Antimicrobial susceptibility testing of Mycobacterium tuberculosis is challenging but critical for patient care. This microtiter plate format offers testing of 12 antimycobacterial drugs and provides minimum inhibitory concentration (MIC) values, which will aid in appropriate treatment.
The rapid detection of antimicrobial resistance is important in the effort to control the increase in resistant Mycobacterium tuberculosis (Mtb). Antimicrobial susceptibility testing (AST) of Mtb has traditionally been performed by the agar method of proportion or by macrobroth testing on an instrument such as the BACTEC (Becton Dickinson, Sparks, MD), VersaTREK (TREK Diagnostics, Cleveland, OH) or BacT/ALERT (bioMérieux, Hazelwood, MO). The agar proportion method, while considered the “gold” standard of AST, is labor intensive and requires calculation of resistance by performing colony counts on drug-containing agar as compared to drug-free agar. If there is ≥1% growth on the drug-containing medium as compared to drug-free medium, the organism is considered resistant to that drug. The macrobroth methods require instrumentation and test break point (“critical”) drug concentrations for the first line drugs (isoniazid, ethambutol, rifampin, and pyrazinamide). The method described here is commercially available in a 96 well microtiter plate format [MYCOTB (TREK Diagnostics)] and contains increasing concentrations of 12 antimicrobials used for treatment of tuberculosis including both first (isoniazid, rifampin, ethambutol) and second line drugs (amikacin, cycloserine, ethionamide, kanamycin, moxifloxacin, ofloxacin, para-aminosalicylic acid, rifabutin, and streptomycin). Pyrazinamide, a first line drug, is not included in the microtiter plate due to its need for acidic test conditions. Advantages of the microtiter system include both ease of set up and faster turn around time (14 days) compared with traditional agar proportion (21 days). In addition, the plate can be set up from inoculum prepared using either broth or solid medium. Since the microtiter plate format is new and since Mtb presents unique safety challenges in the laboratory, this protocol will describe how to safely setup, incubate and read the microtiter plate.
Each laboratory needs to perform a risk assessment in collaboration with their Institutional Biological Safety Officer to determine the appropriate biosafety level for preparation of the inoculum and for pipetting of the inoculum into the plate. In our laboratory, we utilize biosafety level 3 laboratory (BSL3) practices until the microtiter plates are inoculated, and sealed with a plastic adhesive seal. These plates are then placed inside a plastic bag, which is heat-also sealed. Incubation and interpretation reading of the microtiter plate is conducted in a biosafety level 2 laboratory (BSL2).
1. Labeling of materials
2. Technologist preparations to go into the BSL3
3. Preparation of the biological safety cabinet
4. Calibration of the nephelometer
5. Preparation of the Inoculum
6. Inoculation of the microtiter plate
7. Disinfection of materials and biological safety cabinet
8. Incubation
9. Representative results
Interpretation of results:
Sealed AST microtiter plates can be read manually using a mirror as an aid or with an automated plate reader such as the Vizion (TREK Diagnostics). The plates can be examined as soon as 7 days after inoculation. Examine the growth control wells in positions H11 and H12 to determine if they are positive (ie., have a deposit of cells at the bottom of the well). If the growth control wells are not positive, reincubate the plate and re-examine periodically (eg., day 10, day 14) until the growth control wells are positive.
Read purity plates. The blood agar plate should show no growth after 48 hours and the 7H10 purity plate should have confluent growth of one organism type. If contaminated, the AST microtiter test needs to be repeated from a pure culture.
Calculate colony counts from the positive control well using the table below:
Colony Count Key
# colonies counted on plate labeled “1/1” | # colonies counted on plate labeled “1/50” | Inoculum Colony Count (cfu/mL) |
<50 | 0 | <5 X 104 |
50-100 | 0-2 | 5 X 104 to 1 X 105 |
>100 | ≤ 10 | 1 X 105 to 5 X 105 |
>100 | >10 | >5 X 105 |
There may be trailing with para-aminosalicylic acid in some strains of Mycobacterium tuberculosis. This can be interpreted by looking at all wells that have pellets and using the first well that has the same size pellet as the next dilution as the end point. Resistance is rare with this drug.
Figure 1. Representative results using the MYCOTB plate.
Drug abbreviation | Drug | MIC μ/mL |
OFL | ofloxacin | 16 |
MXF | moxifloxacin | 8 |
RIF | rifampin | >16 |
AMI | amikacin | 0.5 |
STR | streptomycin | 16 |
RFB | rifabutin | 8 |
PAS | p-aminosalicylic acid | ≤0.5 |
ETH | ethionamide | 5 |
CYC | cycloserine | 4 |
INH | isoniazid | 2 |
KAN | kanamycin | 1.2 |
EMB | ethambutol | 4.0 |
An example of a AST microtiter plate that has positive growth controls is shown in Figure 1 and the endpoint MIC (μg/ml) for each drug is circled. A study conducted in our laboratory indicated that the AST microtiter plate method is equivalent to the gold standard agar proportion method for susceptibility testing of Mycobacterium tuberculosis. Faster reporting of results was obtained with microtiter AST microtiter plate when compared to the traditional agar proportion method with the final interpretation for AST microtiter plate and agar proportion method at 14 and 21 days, respectively.The AST microtiter plate has the advantage of testing first and second line drugs simultaneously which can help prevent inordinate delays with resistant strains. The AST microtiter plate is also much easier to set up and read than the APM and both a manual mirror and a semi-automated system such as the VIZION can be used to read the plates. The availability of a MIC value for TB drug resistance testing may provide valuable new information to physicians relative to the traditional critical concentration value, especially for those isolates with “borderline” susceptibility.
The authors have nothing to disclose.
We would like to thank the laboratory technologists of the Mayo Clinic Mycobacteriology Laboratory for their help during the study.
Name of the reagent | Company | Catalogue number |
---|---|---|
AST microtiter plates and adhesive seal | TREK Diagnostics, Cleveland Ohio | MYCOTB |
McFarland 0.5 standard | TREK Diagnostics, Cleveland, Ohio | E1041 |
Middlebrook 7H10 plates | Fisher | |
Blood Agar Plates | Fisher | |
Sterile loops 1 μL | Fisher | |
Sterile loops 10 μL | Fisher | |
Sensititre Saline-Tween glass bead broth | TREK Diagnostics, Cleveland, Ohio | 27143 |
7H9 OADC Broth | TREK Diagnostics, Cleveland, Ohio | T3440 |
Long Pipet Tips | Fisher | |
Sterile Troughs | TREK Diagnostics, Cleveland, Ohio | |
M. tuberculosis | ATCC | 27294 |
Pipeters: 1000, 200, 20μL | Fisher | |
Tips 1000, 20, 20 μL | Fisher | |
Multichannel Pipetter | Fisher | |
Incubator 5-10% CO2 | Fisher | |
Plastic bags, small, CO2 permeable | Poly Plastic, Delano, PA | |
TB disinfectant (Such as ProSpray C-60) | Certol International, Commerce City, CO | PSC60/32 |
Mirror Box Reader | Fisher |